included a high-ferritin level (vs low ferritin: 36 vs 67%, Po0.001), a high disease risk at transplantation (vs standard risk: 16 vs 67%, Po0.001) and unrelated donor source (vs related donor: 42 vs 60%, P ¼ 0.009). The high ferritin level (relative to low ferritin; HR, 1.9; 95% CI, 1.12-3.16; P ¼ 0.016), high disease risk (relative to standard risk; HR, 3.6; 95%CI, 2.24-5.89; Po0.001), and unrelated donor source (relative to related donor; HR, 1.9; 95% CI, 1.18-3.2; P ¼ 0.009) were also significantly associated with worse 5-year OS on multivariate analysis. However, subgroup analysis revealed no significant impact of pre-SCT serum ferritin on the outcome of ALL. Patients with high and low serum ferritin levels respectively had the following 5-year OS data ( Figure 1 ): 28 and 72% for patients with AML (Po0.001) vs 58 and 56% for patients with ALL (P ¼ 0.984). On multivariate analysis, high ferritin level (relative to low ferritin; HR, 2.6; 95% CI, 1.33-5.05; P ¼ 0.005) and high disease risk (relative to standard risk; HR, 3.2; 95% CI, 1.74-5.80; Po0.001) at SCT were independently associated with worse 5-year OS in AML patients, but only high disease risk was associated with worse 5-year OS in ALL patients (relative to standard risk; HR, 15.9; 95% CI, 3.34-75.78; P ¼ 0.001). The cumulative incidence of relapse of AML was significantly higher in patients with high ferritin levels than in those with low ferritin levels (53 vs 19%, Po0.001) and in patients with high rather than standard risk (71 vs 19%, Po0.001). For ALL patients, disease risk was a significant predictor of relapse, but there was no relationship between the ferritin level and the relapse rate. The cumulative rate of nonrelapse mortality was also significantly higher in AML patients with high ferritin levels than in those with low ferritin levels (44 vs 14%, P ¼ 0.008), but there was no difference for ALL (18 vs 24%, P ¼ 0.565).
Our results indicate that the pre-SCT serum ferritin level is significantly associated with the outcome of AML, but not ALL. There were no differences of characteristics (including pre-SCT serum ferritin) between the AML and ALL patients in this study. To our knowledge, this is the first report that pre-SCT serum ferritin is not a prognostic factor for ALL, although the reason is not certain. The following issues should be considered regarding the results for ALL: the patient number is small, and various stem cell sources and different regimens were used in this study. Previous studies investigating the clinical significance of pre-SCT serum ferritin in patients with hematologic malignancies have not included a comparison of AML and ALL. Furthermore, the number of ALL patients is smaller than that of AML and/or MDS patients in most reports, 1-5 so we would urge caution when interpreting the results. A larger prospective study would be helpful to confirm these findings.
